View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
November 30, 2021

Krystal’s dystrophic EB gene therapy trial meets primary goal

VYJUVEK was well-tolerated without any drug-associated serious side effects or discontinuations reported in the trial. 

Krystal Biotech has reported that the GEM-3 clinical trial of its experimental gene therapy, beremagene geperpavec (B-VEC), for treating dystrophic epidermolysis bullosa (dystrophic EB) met the primary goal.

Presently called VYJUVEK, B-VEC is a non-invasive topical gene therapy that can offer two copies of the COL7A1 gene when applied to DEB wounds.

It can potentially treat DEB at the molecular level by offering a template to the skin cells of the patient to produce normal COL7 protein to address the basic disease-causing process.

The double-blind, randomised, intra-patient, placebo-controlled trial analysed the safety and efficacy of VYJUVEK to treat dystrophic EB.

A total of 31 subjects aged one to 44 years were enrolled at three study centres.

In the trial, a primary wound pair was detected in each patient of which one was treated with weekly topical VYJUVEK while the other received a placebo.

The trial’s primary goal met statistical significance at six-month timepoints with subjects experiencing full wound healing on treatment with topical VYJUVEK versus placebo.

Findings showed that 67% of wounds in the VYJUVEK arm had complete wound healing at the six-month timepoints as against 22% of wounds treated with placebo.

At the three-month timepoints, 71% of wounds that received VYJUVEK treatment met the secondary goal of investigator evaluated full wound healing versus 20% for the placebo arm.

Furthermore, VYJUVEK was found to be well-tolerated without any treatment-linked serious side effects events or discontinuations noted in the trial.

VYJUVEK’s immunogenicity profile was in line with the previous GEM-1/2 trial where no significant variation in anti-HSV-1 or anti-COL7 antibodies were reported.

Krystal Biotech founder and chief operating officer Suma Krishnan said: “Dystrophic epidermolysis bullosa is referred to as ‘the worst disease you’ve never heard of’, because of the incredibly devastating reality that patients with this genetic condition face, and we are thrilled to announce positive results from our pivotal GEM-3 trial of VYJUVEK, which showed that this topical gene therapy led to durable wound healing in dystrophic EB wounds.

“With these results in hand, we look forward to advancing discussions with regulatory authorities and will work quickly to bring this potential first-ever treatment to patients with dystrophic EB and their families who are in desperate need.”

Based on the latest data, the company plans to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in the first half of next year.

A rare and severe monogenic ailment, dystrophic EB impacts the skin and mucosal tissues.

In March 2018, Krystal filed an IND application with the FDA to commence a Phase I/II trial of its gene therapy for dystrophic EB.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena